Meeting
2016 Genitourinary Cancers Symposium
Pre-clinical rationale for combination PI3K and BRD4 inhibition in advanced prostate cancer.
Authors
Paul Toren
University of Laval, Québec, QC, Canada
Paul Toren , Amina Zoubeidi , Jared Allman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 234)
DOI
10.1200/jco.2016.34.2_suppl.234
Abstract #
234
Poster Bd #
K5
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Comprehensive analysis of AR alterations in cell free DNA from prostate cancer patients.
First Author: Elisa Ledet
Poster
2014 Genitourinary Cancers Symposium
Molecular profiling of advanced refractory prostate cancer.
First Author: Rebecca A. Feldman
Poster
2024 ASCO Genitourinary Cancers Symposium
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
First Author: Guillaume Grisay
Poster
2024 ASCO Genitourinary Cancers Symposium
Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials.
First Author: Alicia K. Morgans